Emerging role for thymic stromal lymphopoietin–responsive regulatory T cells in colorectal cancer progression in humans and mice

• DOI: 10.1126/scitranslmed.abl6960
• Publication Date: 2022-05-18T17:54:24Z
• Authors: Kazushige Obata-N...; Steven de Jesus C...; Alex Hu; Steven F. Ziegler
• Keywords: 0301 basic medicine; Mice; 03 medical and health sciences; Thymic Stromal Lymphopoietin; Animals; Cytokines; Humans; Receptors, Cytokine; Colorectal Neoplasms; T-Lymphocytes, Regulatory; 3. Good health

Recruitment of regulatory T cells (T regs ) to tumors is a hallmark of cancer progression. Tumor-derived factors, such as the cytokine thymic stromal lymphopoietin (TSLP), can influence T reg function in tumors. In our study, we identified a subset of T regs expressing the receptor for TSLP (TSLPR + T regs ) that were increased in colorectal tumors in humans and mice and largely absent in adjacent normal colon. This T reg subset was also found in the peripheral blood of patients with colon cancer but not in the peripheral blood of healthy control subjects. Mechanistically, we found that this T reg subset coexpressed the interleukin-33 (IL-33) receptor [suppressor of tumorigenicity 2 (ST2)] and had high programmed cell death 1 (PD-1) and cytotoxic lymphocyte–associated antigen 4 (CTLA-4) expression, regulated in part by the transcription factor Mef2c. T reg -specific deletion of TSLPR, but not ST2, was associated with a reduction in tumor number and size with concomitant increase in T H 1 cells in tumors in chemically induced mouse models of colorectal cancer. Therapeutic blockade of TSLP using TSLP-specific monoclonal antibodies effectively inhibited the progression of colorectal tumors in this mouse model. Collectively, these data suggest that TSLP controls the progression of colorectal cancer through regulation of tumor-specific T reg function and represents a potential therapeutic target that requires further investigation.